FDA Grants Interchangeable Status to Humira Biosimilar; Payers Should Prepare Now for 2023 Launches

close-up-shot-of-vaccines-glass-bottles
November 16

Less than three months after granting interchangeable status to a biosimilar for the first time, the FDA has approved that status for a second biosimilar, Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo (adalimumab-adbm). It and multiple other biosimilars of AbbVie Inc.’s Humira (adalimumab) are slated to come onto the U.S. market in 2023, but plans should be preparing now for the drugs’ launches, say industry experts. Still, a handful of factors could pose an issue with the agents’ taking market share from the reference product.

0
0 Comments

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/08/Specialty_Pharmacy_Interchangeable_Biosimilar.jpg
August 4

What Might Be Impact of First Interchangeable Biosimilar?

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-RADAR-on-Drug-Benefits-Savings-From-Interchangeable-Biosimilars-May-Be-Muted.jpg
October 28

Savings From Interchangeable Biosimilars May Be Muted

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/07/Drug_Benefits_Biosimilars.jpg
August 12

Biosimilars Get Call-Out in PBMs’ 2nd Quarter Earnings Calls

Read More
directory-of-health-plans-test-drive-directory-of-health-plans-ad

The Latest

Premium Categories

meet-the-expert-webinar-navigating-the-complex-us-payer-landscape-to-grow-your-business-ad

Meet Our Reporters

Tags

AIS's Directory of Health Plans Behavioral Health Benefit Design Benefit Management Biosimilars Cell and Gene Therapies Consumer Engagement COVID Data & Analytics Drug Approvals Drug Pricing Dual Eligibles Employer Group Health Plans Executive Compensation FDA FDA Specialty Approvals Fee-for-service Medicare Financial Results Infographics Infusion Therapy legislation & regulation Managed Medicaid Market access Medical Costs Medicare Advantage Medicare Advantage Rx Drug Medicare Part D Membership Growth Mergers & Acquisitions News Briefs Oncology Payer Portrait PBMs; Pharmacy Benefit Manager Policy & Politics Premiums Reimbursement Site of Care Management Social Determinants of Health Specialty Drugs Stock Performance telehealth Value-based Arrangements

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today